Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment

A prospective study in Israel evaluated the durability of response to the SARS-CoV-2 BNT162b2 vaccination among patients undergoing active treatment for solid tumors and among control persons. The study found that approximately 4 months after the second vaccination dose the seropositivity rate among the patients was high (87%). The median IgG titer in patients and control persons decreased over time. The IgG titers were statistically significantly lower in patients versus controls.